TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02679001

Intervention type: DRUG
Intervention: TNF inhibitor/TCZ
Description: Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
Study: NCT04745546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-JAAA Stent Graft System
Description: The abdominal aorta stent graft system consists of the abdominal aorta embedded stent system, the abdominal aorta bifurcation stent system and the extended stent system. The abdominal aorta embedded stent has two embedded branch stents and two fenestrations. It can be combined with a peripheral small stent system of appropriate specifications to reconstruct the superior mesenteric artery, bilateral renal arteries and keep the abdominal trunk unobstructed. At the same time, the combination of the abdominal aorta embedded stent, the abdominal aorta bifurcation stent and the extended stent can solve the proximal renal and transrenal abdominal aortic aneurysm lesions with the upper edge of the abdominal aortic aneurysm body and the lower edge of the superior mesenteric artery opening ≥ 5 mm.
Study: NCT03096821

Intervention type: DRUG
Intervention: ngFDS selected treatment
Description: Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
Study: NCT02597998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-BI 409306
Study: NCT00366899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7 valent pneumococcal conjugate vaccine
Description: Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
Study: NCT01352325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: system constellations seminar
Description: individual-centered intervention in a group setting, duration 3 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: system constellations seminar
Description: individual-centered intervention in a group setting, duration 3 days
Study: NCT01127022

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: choline chloride
Description: Women will consume a diet providing 380 mg/d total choline plus 100 mg/d supplemental choline \[from choline chloride\] for a total choline intake of 480 mg/d. The choline chloride will be administered in cran-grape juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline Chloride
Description: Women will consume a diet providing 380 mg/d total choline plus 550 mg/d supplemental choline \[from choline chloride\] for a total choline intake of 930 mg/d. The choline chloride will be administered in cran-grape juice.
Study: NCT03021720

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial access
Description: Location of arterial puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial access
Description: Location of arterial puncture
Study: NCT02958709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose: RIF, INH, PZA, EMB
Description: high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose: RIF, INH, PZA, LEVO
Description: high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care: RIF, INH, PZA, EMB
Description: standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
Study: NCT04111731

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon pulmonary vein isolation
Description: Catheter ablation using cryoballoon pulmonary vein isolation. Utilisation of a 'cold balloon' (Cryoenergy or cryoballoon ablation) to freeze the bases of the 4 pulmonary veins to achieve electrical isolation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency pulmonary vein isolation
Description: Catheter ablation using radiofrequency energy to achieve pulmonary vein isolation. Radiofrequency energy is delivered through the tip of a catheter to make tiny burns (ablation lesions) around the outlines of the 4 pulmonary veins at their bases

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeat electrophysiological study
Description: All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeat electrophysiological study
Description: All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial posterior wall isolation
Description: The left atrial posterior wall will be isolated in Group 2 participants (those who received radiofrequency ablation at the index procedure) during the repeat electrophysiological study in 2 months
Study: NCT01743157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochemo + bevacizumab then ipilimumab
Description: Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, \& 4)
Study: NCT05703308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Menstrual Blood Stem Cells
Description: The menstrual blood of patients in the MenSCs treatment group was collected in sterile menstrual cups on the second day of menstruation, and directly transferred to a class B clean room for MSC isolation and culture. All cell quality control studies were performed prior to the International Conference of Harmonization Q2 (ICH Q2) guidelines. The density of the final product was 20×106 cells/ml. 150 μl of the prepared suspension was injected intravaginally into each ovary of the patient under general anaesthesia
Study: NCT02946762

Intervention type: OTHER
Group type: OTHER
Intervention: Test and treat
Description: All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
Study: NCT00605709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: API 31510 Topical Cream
Description: Topical treatments to lesion twice daily of randomized treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: API 31510 Topical Cream
Description: Topical treatments to lesion twice daily of randomized treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: API 31510 Topical Cream
Description: Topical treatments to lesion twice daily of randomized treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: API 31510 Topical Cream
Description: Topical treatments to lesion twice daily of randomized treatments.
Study: NCT04013425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ice Cream Cone Technique
Description: Guided bone regeneration
Study: NCT03155048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral estrogen replacement therapy
Description: oral estradiol group for endometrial preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol transdermal patch
Description: transdermal estradiol group for endometrial preparation
Study: NCT03178500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 50mg
Description: stair-step clomiphene adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 50mg
Description: stair-step clomiphene adminstration
Study: NCT06114251

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of postoperative recurrence of liver cancer
Description: HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of postoperative recurrence of liver cancer
Description: HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation.
Study: NCT02518581

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Doubly labelled water method
Description: DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE). After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions. The resulting TEE measurement represents an integral value over the measurement period.
Study: NCT00414466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraspinal Gabapentin
Description: Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraspinal Gabapentin
Description: Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraspinal Gabapentin
Description: Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intraspinal Gabapentin
Description: Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
Study: NCT02101346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed High Fat Diet
Description: Healthy, Round 1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated fat diet
Description: Healthy, Round 1 Healthy, Round 2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saturated fat diet
Description: Healthy, Round 1 Healthy, Round 2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat diet
Description: Healthy, Round 1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat diet
Description: Healthy, Round 1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Triolein 13C
Description: Healthy, Round 2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fat
Description: Healthy, Round 1
Study: NCT03720262

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mesh reinforcement
Description: Reinforcement of the abdominal wall with Ultrapro Advanced.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No reinforcement
Description: Suturing the abdominal wall without mesh reinforcement
Study: NCT03760211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel Gaming Adherence Intervention
Description: Combination of electronic medication monitoring device with Information-Motivation-Behavior based mobile gaming application tailored for those living with HIV and adherence-based text messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual +
Description: Combination of electronic medication monitoring device and non-HIV related mobile gaming application
Study: NCT01078025

Intervention type: PROCEDURE
Intervention: Smear test vaginally, intraabdominally
Description: Pre- and intraoperative smear tests of the vagina and douglas are performed.

Intervention type: PROCEDURE
Intervention: Smear test vaginally, intraabdominally
Description: Pre- and intraoperative smear tests of the vagina and douglas are performed.
Study: NCT00826930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate (TSC)
Description: Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate (TSC)
Description: Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate (TSC)
Description: Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate (TSC)
Description: Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate (TSC)
Description: Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate (TSC)
Description: Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate (TSC)
Description: Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans Sodium Crocetinate (TSC)
Description: Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
Study: NCT01706536

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: EP-101 Placebo AM + EP-101 Placebo PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 12.5 mcg
Description: EP-101 12.5 mcg AM + EP-101 12.5 mcg PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 25 mcg
Description: EP-101 25 mcg AM + EP-101 25 mcg PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 50 mcg
Description: EP-101 50 mcg AM + EP-101 50 mcg PM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-101 100 mcg
Description: EP-101 100 mcg AM + EP-101 100 mcg PM
Study: NCT03681509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Pramipexole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose placebo capsule
Study: NCT00775177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate 100mg tablets
Description: Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline monohydrate 100mg tablets
Description: Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
Study: NCT01524653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg po od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg po od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 mg po od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 mg po od
Study: NCT05390437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional intervention with Ready to use theraputic food (RUTF) and prebiotic GOS (galacto oligosaccharides) in combination
Description: 4gm of prebiotic GOS ( Galactooligosaccharides) and Ready to use theraputic food (RUTF) as per WHO standard on daily basis for 60 Days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ready to use theraputic food (RUTF) and Starch (placebo)
Description: Ready to use therapeutic food (RUTF) as per WHO standard and (Starch Placebo) soluble in water and mix in food on daily basis for 60 Days
Study: NCT06059326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 10 mg
Description: Tablet, HSK7653 10 mg Q2W, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 25 mg
Description: Tablet, HSK7653 25 mg Q2W, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 50 mg
Description: Tablet, HSK7653 50 mg Q2W, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 0 mg Q2W, 12 weeks
Study: NCT03207581

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Professional Coaching
Description: Professional, individualized coaching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Coaching
Description: Professional, individualized coaching
Study: NCT00595608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterimar Spray
Description: Post-op nasal spray, three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic homemade nasal saline spray (salt and water)
Description: post op nasal saline spray in syringe, three times a day
Study: NCT01239121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIE-Enhanced Medication Reconciliation
Description: Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist

Intervention type: OTHER
Group type: OTHER
Intervention: HIE-Enhanced Medication Reconciliation
Description: Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medication Reconciliation without HIE
Description: Medication reconciliation implemented by a pharmacist without regional health information exchange
Study: NCT01677078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronavigation system
Description: Neuronavigation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard localisation method
Description: Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
Study: NCT00758186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency endoscopic colonic stenting
Description: Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency surgery
Description: Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
Study: NCT03048500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02602925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose decrease
Description: Treatment strategy change: dose decrease based on PASI and DLQI

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study: NCT03528200

Intervention type: OTHER
Group type: OTHER
Intervention: Contrast
Description: The scan requires that the patient lie still on a hard surface for about 5-10 minutes. Before the scan, they will have a special fluid called contrast dye injected through the IV in their arm. This contrast dye helps to see the blood in the arteries using x-ray pictures.~After the IV dyna CBV is completed, they will have their routine conventional angiography to evaluate the lesion for embolizable arteries as part of routine clinical care. If the patient undergoes embolization of the lesion (as part of the standard of care), a post embolization Dyna CBV will be performed.
Study: NCT02977026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CYD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AHC
Study: NCT01246830

Intervention type: RADIATION
Intervention: Panoramic radiograph, Cephalometric radiograph
Description: 2D images that are used for orthodontic treatment planning

Intervention type: RADIATION
Intervention: Cone-beam computed tomography (CBCT)
Description: CBCT data will be used in 3D cephalometric analysis softwares
Study: NCT00144625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/4weeks
Study: NCT04619810

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse intervention program
Description: Implementation of a specific care program for patients receiving immunotherapy for lung cancer
Study: NCT02625454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen
Description: 1000 mg Acetaminophen q 6 hours, given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Acetaminophen
Description: 1000 mg Acetaminophen q 6 hours given orally